Glenview Trust CO Vertex Pharmaceuticals Inc Transaction History

Glenview Trust CO

$4.59 Billion
Q1 2024

A detailed history of Glenview Trust CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Glenview Trust CO holds 6,570 shares of VRTX stock, worth $3.11 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

6,570

Previous 6,390 2.82%

Holding current value

$3.11 Million

Previous $2.6 Million 5.62%

% of portfolio

0.06%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $73,384 - $80,294	180 Added 2.82%	6,570 $2.75 Million
Q4 2023 Feb 12, 2024	BUY	$343.0 - $410.68 $33,614 - $40,246	98 Added 1.56%	6,390 $2.6 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $17,921 - $20,058	57 Added 0.91%	6,292 $2.21 Million
Q1 2023 May 09, 2023	SELL	$283.23 - $323.1 $43,900 - $50,080	-155 Reduced 2.43%	6,235 $1.96 Million
Q4 2022 Feb 08, 2023	BUY	$285.76 - $321.48 $150,595 - $169,419	527 Added 8.99%	6,390 $1.85 Million

Q3 2022 Nov 04, 2022	BUY	$273.83 - $305.53 $187,299 - $208,982	684 Added 13.21%	5,863 $1.7 Million
Q2 2022 Aug 10, 2022	BUY	$234.96 - $292.55 $5,639 - $7,021	24 Added 0.47%	5,179 $1.46 Million
Q1 2022 May 11, 2022	BUY	$221.42 - $260.97 $1.14 Million - $1.35 Million	5,155 New	5,155 $1.35 Million
Q4 2021 Feb 10, 2022	SELL	$177.01 - $223.45 $688,568 - $869,220	-3,890 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $347,361 - $388,725	1,915 Added 96.96%	3,890 $705,000
Q2 2021 Aug 11, 2021	BUY	$187.49 - $221.1 $370,292 - $436,672	1,975 New	1,975 $398,000

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenview Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Glenview Trust CO with notifications on news.

Account

Glenview Trust CO Vertex Pharmaceuticals Inc Transaction History